← Leaderboards
Amir Goldkorn
University Of Southern California
$4,457,420
Attributed
$9,782,572
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,782,572 · 7
By mechanism
R01$7,769,228 · 3
P30$833,097 · 2
K08$759,846 · 1
R21$420,401 · 1
Top collaborators
- Vinay Duddalwar5 shared
- Sue Ann Ingles5 shared
- Jacek Pinski5 shared
- Timothy J. Triche5 shared
- Richard James Cote2 shared
- Scott E Fraser2 shared
- Masahiro Kitano2 shared
- Andrew David Smith2 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Ellis Meng$15,028,365
- Dong Song$6,229,513
- Jacek Pinski$3,050,227
- Richard James Cote$13,022,506
- Timothy J. Triche$21,258,785
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInsightResponseTumorPathway InteractionsMalignant NeoplasmsResearch PersonnelPhenotypeBasePrimary NeoplasmBlood SpecimenOncologyMolecularProspectiveNeoplasm Circulating CellsImageTissuesDisseminated Malignant NeoplasmFoundationsProgression-Free SurvivalsCollaborationsMalignant Neoplasm Of ProstateGenomicsGenes
Grant awards (24)
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$689,813
R01 · FY2025 · CA · contact PI
Liquid Biopsy Core$204,368
P30 · FY2025 · CA · contact PI
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$655,325
R01 · FY2024 · CA · contact PI
Liquid Biopsy Core$194,588
P30 · FY2024 · CA · contact PI
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$676,022
R01 · FY2023 · CA · contact PI
Liquid Biopsy Core$216,213
P30 · FY2023 · CA · contact PI
Early tumorigenesis in vivo imaging, scRNA-seq to functional assays$188,988
R21 · FY2023 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$676,023
R01 · FY2022 · CA · contact PI
Early tumorigenesis in vivo imaging, scRNA-seq to functional assays$231,413
R21 · FY2022 · CA
Liquid Biopsy Core$217,928
P30 · FY2022 · CA · contact PI
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$706,071
R01 · FY2021 · CA · contact PI
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$662,099
R01 · FY2018 · CA · contact PI
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$665,642
R01 · FY2017 · CA · contact PI
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$669,388
R01 · FY2016 · CA · contact PI
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$676,561
R01 · FY2015 · CA · contact PI
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$674,482
R01 · FY2014 · CA · contact PI
Targeting Cancer with Telomerase Interference$131,220
K08 · FY2011 · CA · contact PI
Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial$493,402
R01 · FY2010 · CA
Targeting Cancer with Telomerase Interference$131,220
K08 · FY2010 · CA · contact PI
Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial$524,400
R01 · FY2009 · CA
Targeting Cancer with Telomerase Interference$130,817
K08 · FY2009 · CA · contact PI
Targeting Cancer with Telomerase Interference$107,996
K08 · FY2009 · CA · contact PI
Targeting Cancer with Telomerase Interference$129,600
K08 · FY2008 · CA · contact PI
Targeting Cancer with Telomerase Interference$128,993
K08 · FY2007 · CA · contact PI